Seeking Alpha

Microcap biopharmaceutical researcher Adventrx Pharmaceuticals (ANX +11.2%) gets a pop today...

Microcap biopharmaceutical researcher Adventrx Pharmaceuticals (ANX +11.2%) gets a pop today after announcing that it's initiated patient recruitment for its Phase 3 clinical study of ANX-188 in sickle cell disease. Santosh Vetticaden, the company's Chief Medical Officer, says the drug "has the potential to be the first FDA-approved product for sickle cell disease vaso-occlusive crisis in fifteen years."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)